Salipro Biotech

Salipro Biotech, founded in 2013 and based in Stockholm, Sweden, is a platform biotechnology company tackling the 'undruggable' proteome. Its core innovation is the Salipro® platform, which stabilizes membrane proteins like GPCRs, ion channels, and transporters in a native lipid environment, creating high-quality targets for drug discovery. The company leverages this platform through strategic collaborations with top-tier pharma and biotech partners and is advancing its own internal pipeline. With a strong and expanding intellectual property estate, Salipro is positioned as a key enabler for novel drug discovery against historically difficult targets.

Proprietary Salipro® platform uses engineered saposin proteins to stabilize membrane proteins (GPCRs, ion channels, transporters) in native lipid nanoparticles for drug discovery applications like DEL screening, structural biology, and antibody generation.

Salipro competes in the membrane protein stabilization space with other technologies like nanodiscs (using MSP or other scaffold proteins), styrene-maleic acid lipid particles (SMALPs), and certain detergent-based methods. Its key differentiator is the use of saposin proteins to create stable, native-like particles suitable for a wide range of discovery applications, as evidenced by its high-profile collaborations.